Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Jennison Associates LLC

Jennison Associates LLC lessened its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 10.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 716,933 shares of the company’s stock after selling 80,748 shares during the quarter. Jennison Associates LLC’s holdings in Kymera Therapeutics were worth $28,842,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company boosted its stake in shares of Kymera Therapeutics by 13.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 130,077 shares of the company’s stock worth $3,883,000 after acquiring an additional 15,320 shares in the last quarter. SG Americas Securities LLC raised its holdings in Kymera Therapeutics by 35.2% in the 3rd quarter. SG Americas Securities LLC now owns 14,719 shares of the company’s stock worth $697,000 after purchasing an additional 3,832 shares during the period. Handelsbanken Fonder AB boosted its position in Kymera Therapeutics by 12.3% during the third quarter. Handelsbanken Fonder AB now owns 17,300 shares of the company’s stock worth $819,000 after purchasing an additional 1,900 shares in the last quarter. Values First Advisors Inc. acquired a new stake in Kymera Therapeutics in the third quarter valued at approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Kymera Therapeutics by 27.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after buying an additional 504 shares in the last quarter.

Insiders Place Their Bets

In other news, insider Ellen Chiniara sold 3,129 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $41.75, for a total value of $130,635.75. Following the sale, the insider now directly owns 54,826 shares of the company’s stock, valued at approximately $2,288,985.50. The trade was a 5.40 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 15.82% of the stock is owned by insiders.

Kymera Therapeutics Stock Up 0.6 %

Shares of KYMR opened at $38.73 on Wednesday. The stock has a fifty day simple moving average of $42.12 and a two-hundred day simple moving average of $44.65. The company has a market capitalization of $2.51 billion, a PE ratio of -16.55 and a beta of 2.18. Kymera Therapeutics, Inc. has a 52-week low of $29.24 and a 52-week high of $53.27.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Stephens reiterated an “overweight” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Guggenheim increased their price objective on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a report on Friday, November 1st. Morgan Stanley lifted their target price on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 6th. Leerink Partners restated an “outperform” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Friday, December 27th. Finally, BMO Capital Markets began coverage on Kymera Therapeutics in a report on Friday, December 6th. They issued a “market perform” rating and a $55.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $55.06.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.